Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, Jorge Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Susanne Saussele, Francois Mahon, Tim H. Brümmendorf, Shruti Kapoor, Tracey McCulloch, Peter Schuld, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 6388.

https://doi.org/10.1182/blood-2023-186773

Published: 2023

Journal Articles

ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase

Andreas Hochhaus, Susanne Saussele, Francois-Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, Tim H. Brümmendorf

Blood (2022) 140 (Supplement 1): 6787–6788.

https://doi.org/10.1182/blood-2022-163051

Published: 2022

Journal Articles

Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)

Peter Schuld, PhD, Stephan Grzesiek, PhD, Johannes Schlotte, Judith M Habazettl, PhD, Wolfgang Jahnke, PhD, Louise Barys, MS, Sandra W Cowan-Jacob, PhD, Alice Loo, MS, Andrea Wiget, Paul W. Manley, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-140968

Published: 2020

Journal Articles

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Blood (2013) 122 (21): 4030.

https://doi.org/10.1182/blood.V122.21.4030.4030

Published: 2013

Journal Articles

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Blood (2011) 118 (21): 247.

https://doi.org/10.1182/blood.V118.21.247.247

Published: 2011

Journal Articles

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Francis J. Giles, MB, MD, FRCPI, FRCPath, Gianantonio Rosti, MD, Gert Ossenkoppele, MD, PhD, Michel Tulliez, Jesper Stentoft, MD, PhD, Aristoteles Giagounidis, MD, Francesco Nobile, MD, Philipp D. le Coutre, MD, Norbert Gattermann, MD, Laimonas Griskevicius, Nicholas C.P. Cross, PhD, FRCPath, Sarah Hill, BSc (hons), PhD, MICR, Peter Schuld, PhD, Angela Pellegrino, Domenico Magazzù, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2759.

https://doi.org/10.1182/blood.V118.21.2759.2759

Published: 2011

Journal Articles

Bcr-Abl and Wilms Tumor Gene (WT1) Kinetics in Nilotinib (AMN107) Treated CML Patients.

Michaela Schwarz, MD, Gokben Baskaynak, MD, Seval Turkmen, MD, Peter Schuld, MD, Bernd Dorken, MD, Peter Daniel, MD, le Coutre Philipp

Blood (2006) 108 (11): 2336.

https://doi.org/10.1182/blood.V108.11.2336.2336

Published: 2006

Journal Articles

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Paul La Rosée, MD, Susanne Holm-Eriksen, Thomas Ernst, MD, Heiko König, MD, Philipp Erben, MD, Martin Müller, MD, Thomas Schenk, MD, Michael Emig, MD, Anja Binckebanck, MD, Lydia Wunderle, MD, Leila Alland, MD, Peter Schuld, MD, Rüdiger Hehlmann, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 497.

https://doi.org/10.1182/blood.V106.11.497.497

Published: 2005

NARROW

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase

Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Bcr-Abl and Wilms Tumor Gene (WT1) Kinetics in Nilotinib (AMN107) Treated CML Patients.

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only